Firstly, although the study underscores the selective targeting of EpCAM-expressing cancer cells, the observed decline in NK cells, macrophages, and MDSCs – presumably attributable to Fc receptor binding – gives rise to concerns regarding potential off-target effects on immune cell populations that are crucial for antitumor responses. The gene discussed is EPCAM; the disease is cancer.